Pandora Wealth Inc. Makes New Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Key Points

• Pandora Wealth Inc. has invested approximately $3.3 million in TG Therapeutics, Inc. (NASDAQ:TGTX), acquiring 83,700 shares, making it the firm's 11th largest holding.
• A variety of investors, including NBC Securities Inc. and Golden State Wealth Management LLC, have significantly increased their stakes in TG Therapeutics, with institutional investors currently owning 58.58% of the stock.
• TG Therapeutics reported $0.17 earnings per share for the last quarter, missing estimates of $0.32, while also showing a 92.1% increase in revenue year-over-year.

Pandora Wealth Inc. acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 83,700 shares of the biopharmaceutical company's stock, valued at approximately $3,300,000. TG Therapeutics makes up 2.2% of Pandora Wealth Inc.'s portfolio, making the stock its 11th largest holding. Pandora Wealth Inc. owned about 0.05% of TG Therapeutics at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. NBC Securities Inc. boosted its holdings in shares of TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 823 shares during the period. Golden State Wealth Management LLC boosted its holdings in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 433 shares during the period. Vermillion Wealth Management Inc. acquired a new position in shares of TG Therapeutics in the 4th quarter valued at about $30,000. USA Financial Formulas acquired a new position in shares of TG Therapeutics in the 1st quarter valued at about $57,000. Finally, Quadrant Capital Group LLC boosted its holdings in shares of TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after buying an additional 975 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the sale, the director directly owned 228,816 shares in the company, valued at approximately $8,452,463.04. The trade was a 4.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 10.64% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 price target for the company in a report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $46.25.

TG Therapeutics Trading Down 4.2%

Shares of NASDAQ:TGTX opened at $26.71 on Friday. The company has a market cap of $4.24 billion, a PE ratio of 72.19 and a beta of 1.95. The company's 50-day moving average price is $36.10 and its 200 day moving average price is $35.95. TG Therapeutics, Inc. has a fifty-two week low of $19.45 and a fifty-two week high of $46.48. The company has a quick ratio of 3.04, a current ratio of 4.02 and a debt-to-equity ratio of 1.03.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 27.83%. The company's revenue for the quarter was up 92.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.04 earnings per share. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.